Semin Liver Dis 2012; 32(04): 348-359
DOI: 10.1055/s-0032-1329906
Editors' Choice
Thieme Medical Publishers 333 Seventh Avenue, New York, NY 10001, USA.

Heterogeneity of Patients with Intermediate (BCLC B) Hepatocellular Carcinoma: Proposal for a Subclassification to Facilitate Treatment Decisions

Luigi Bolondi
1   Division of Internal Medicine, Department of Digestive Disease and Internal Medicine, University of Bologna, S. Orsola-Malpighi Hospital, Bologna, Italy
,
Andrew Burroughs
2   The Royal Free Sheila Sherlock Liver Centre, The Royal Free Hospital and UCL Institute for Liver and Digestive Health, UCL London, London, UK
,
Jean-François Dufour
3   University Clinic for Visceral Surgery and Medicine, Inselspital, Bern and Hepatology, Department of Clinical Research, University of Bern, Bern, Switzerland
,
Peter R. Galle
4   University Medical Center, I. Medical Department, Johannes Gutenberg University, Mainz, Germany
,
Vincenzo Mazzaferro
5   Istituto Nazionale Tumori (National Cancer Institute) IRCCS Foundation, Milan, Italy
,
Fabio Piscaglia
1   Division of Internal Medicine, Department of Digestive Disease and Internal Medicine, University of Bologna, S. Orsola-Malpighi Hospital, Bologna, Italy
,
Jean Luc Raoul
6   Department of Medical Oncology, Institut Paoli-Calmettes, Marseille, France
,
Bruno Sangro
7   Liver Unit, Clinica Universidad de Navarra, and Centro de Investigacion Biomedica en Red de Enfermedades Hepaticas y Digestivas (CIBERehd), Pamplona, Spain
› Institutsangaben
Weitere Informationen

Publikationsverlauf

Publikationsdatum:
08. Februar 2013 (online)

Abstract

The intermediate stage of hepatocellular carcinoma (HCC) comprises a highly heterogeneous patient population and therefore poses unique challenges for therapeutic management, different from the early and advanced stages. Patients classified as having intermediate HCC by the Barcelona Clinic Liver Cancer (BCLC) staging system present with varying tumor burden and liver function. Transarterial chemoembolization (TACE) is currently recommended as the standard of care in this setting, but there is considerable variation in the clinical benefit patients derive from this treatment.

In April 2012, a panel of experts convened to discuss unresolved issues surrounding the application of current guidelines when managing patients with intermediate HCC. The meeting explored the applicability of a subclassification system for intermediate HCC patients to tailor therapeutic interventions based on the evidence available to date and expert opinion. The present report summarizes the proposal of the expert panel: four substages of intermediate HCC patients, B1 to B4.

 
  • References

  • 1 National Cancer Institute. SEER Stat Fact Sheets: Liver and Intrahepatic Bile Duct. Available at: http://seer.cancer.gov/statfacts/html/livibd.html . Accessed August 24, 2012.
  • 2 Berrino F, De Angelis R, Sant M , et al; EUROCARE Working group. Survival for eight major cancers and all cancers combined for European adults diagnosed in 1995-99: results of the EUROCARE-4 study. Lancet Oncol 2007; 8 (9) 773-783
  • 3 Verdecchia A, Francisci S, Brenner H , et al; EUROCARE-4 Working Group. Recent cancer survival in Europe: a 2000-02 period analysis of EUROCARE-4 data. Lancet Oncol 2007; 8 (9) 784-796
  • 4 Forner A, Llovet JM, Bruix J. Hepatocellular carcinoma. Lancet 2012; 379 (9822) 1245-1255
  • 5 Marrero JA, Fontana RJ, Barrat A , et al. Prognosis of hepatocellular carcinoma: comparison of 7 staging systems in an American cohort. Hepatology 2005; 41 (4) 707-716
  • 6 Cillo U, Vitale A, Grigoletto F , et al. Prospective validation of the Barcelona Clinic Liver Cancer staging system. J Hepatol 2006; 44 (4) 723-731
  • 7 Guglielmi A, Ruzzenente A, Pachera S , et al. Comparison of seven staging systems in cirrhotic patients with hepatocellular carcinoma in a cohort of patients who underwent radiofrequency ablation with complete response. Am J Gastroenterol 2008; 103 (3) 597-604
  • 8 Bruix J, Sherman M. American Association for the Study of Liver Diseases. Management of hepatocellular carcinoma: an update. Hepatology 2011; 53 (3) 1020-1022
  • 9 European Association For The Study Of The Liver; European Organisation For Research And Treatment Of Cancer. EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma. J Hepatol 2012; 56 (4) 908-943
  • 10 Schwartz M, Roayaie S, Konstadoulakis M. Strategies for the management of hepatocellular carcinoma. Nat Clin Pract Oncol 2007; 4 (7) 424-432
  • 11 Llovet JM, Burroughs A, Bruix J. Hepatocellular carcinoma. Lancet 2003; 362 (9399) 1907-1917
  • 12 Clark HP, Carson WF, Kavanagh PV, Ho CP, Shen P, Zagoria RJ. Staging and current treatment of hepatocellular carcinoma. Radiographics 2005; 25 (Suppl. 01) S3-S23
  • 13 Llovet JM. Treatment of Hepatocellular Carcinoma. Curr Treat Options Gastroenterol 2004; 7 (6) 431-441
  • 14 Llovet JM, Bruix J. Systematic review of randomized trials for unresectable hepatocellular carcinoma: Chemoembolization improves survival. Hepatology 2003; 37 (2) 429-442
  • 15 Piscaglia F, Bolondi L. The intermediate hepatocellular carcinoma stage: Should treatment be expanded?. Dig Liver Dis 2010; 42 (Suppl. 03) S258-S263
  • 16 D'Avola D, Iñarrairaegui M, Pardo F , et al. Prognosis of hepatocellular carcinoma in relation to treatment across BCLC stages. Ann Surg Oncol 2011; 18 (7) 1964-1971
  • 17 Marelli L, Stigliano R, Triantos C , et al. Transarterial therapy for hepatocellular carcinoma: which technique is more effective? A systematic review of cohort and randomized studies. Cardiovasc Intervent Radiol 2007; 30 (1) 6-25
  • 18 Tsochatzis EA, Germani G, Burroughs AK. Transarterial chemoembolization, transarterial chemotherapy, and intra-arterial chemotherapy for hepatocellular carcinoma treatment. Semin Oncol 2010; 37 (2) 89-93
  • 19 Terzi E, Golfieri R, Piscaglia F , et al. Response rate and clinical outcome of HCC after first and repeated cTACE performed “on demand”. J Hepatol 2012; ; Epub ahead of print
  • 20 Takayasu K, Arii S, Kudo M , et al. Superselective transarterial chemoembolization for hepatocellular carcinoma. Validation of treatment algorithm proposed by Japanese guidelines. J Hepatol 2012; 56 (4) 886-892
  • 21 Oliveri RS, Wetterslev J, Gluud C. Transarterial (chemo)embolisation for unresectable hepatocellular carcinoma. Cochrane Database Syst Rev 2011; (3) CD004787
  • 22 Lencioni R, Llovet JM. Modified RECIST (mRECIST) assessment for hepatocellular carcinoma. Semin Liver Dis 2010; 30 (1) 52-60
  • 23 Gillmore R, Stuart S, Kirkwood A , et al. EASL and mRECIST responses are independent prognostic factors for survival in hepatocellular cancer patients treated with transarterial embolization. J Hepatol 2011; 55 (6) 1309-1316
  • 24 Cammà C, Schepis F, Orlando A , et al. Transarterial chemoembolization for unresectable hepatocellular carcinoma: meta-analysis of randomized controlled trials. Radiology 2002; 224 (1) 47-54
  • 25 Raoul JL, Sangro B, Forner A , et al. Evolving strategies for the management of intermediate-stage hepatocellular carcinoma: available evidence and expert opinion on the use of transarterial chemoembolization. Cancer Treat Rev 2011; 37 (3) 212-220
  • 26 Lencioni R. Loco-regional treatment of hepatocellular carcinoma. Hepatology 2010; 52 (2) 762-773
  • 27 Meyer T, Roughton M, Yu D , et al. A randomized phase II/III trial of three weekly cisplatin based transarterial chemoembolization (TACE) versus embolization (TAE) alone for hepatocellular cancer (HCC) [Abstract 4025]. J Clin Oncol 2010; 28 (suppl): 15s
  • 28 Llovet JM, Real MI, Montaña X , et al; Barcelona Liver Cancer Group. Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial. Lancet 2002; 359 (9319) 1734-1739
  • 29 Golfieri R, Cappelli A, Cucchetti A , et al. Efficacy of selective transarterial chemoembolization in inducing tumor necrosis in small (<5 cm) hepatocellular carcinomas. Hepatology 2011; 53 (5) 1580-1589
  • 30 Varela M, Real MI, Burrel M , et al. Chemoembolization of hepatocellular carcinoma with drug eluting beads: efficacy and doxorubicin pharmacokinetics. J Hepatol 2007; 46 (3) 474-481
  • 31 Lammer J, Malagari K, Vogl T , et al; PRECISION V Investigators. Prospective randomized study of doxorubicin-eluting-bead embolization in the treatment of hepatocellular carcinoma: results of the PRECISION V study. Cardiovasc Intervent Radiol 2010; 33 (1) 41-52
  • 32 Malagari K, Pomoni M, Kelekis A , et al. Prospective randomized comparison of chemoembolization with doxorubicin-eluting beads and bland embolization with BeadBlock for hepatocellular carcinoma. Cardiovasc Intervent Radiol 2010; 33 (3) 541-551
  • 33 Grieco A, Marcoccia S, Miele L , et al. Transarterial chemoembolization (TACE) for unresectable hepatocellular carcinoma in cirrhotics: functional hepatic reserve and survival. Hepatogastroenterology 2003; 50 (49) 207-212
  • 34 Saccheri S, Lovaria A, Sangiovanni A , et al. Segmental transcatheter arterial chemoembolization treatment in patients with cirrhosis and inoperable hepatocellular carcinomas. J Vasc Interv Radiol 2002; 13 (10) 995-999
  • 35 Lu W, Li Y, He X, Chen Y. Transcatheter arterial chemoembolization for hepatocellular carcinoma in patients with cirrhosis: evaluation of two kinds of dosages of anticancer drugs and analysis of prognostic factors. Hepatogastroenterology 2003; 50 (54) 2079-2083
  • 36 Ikeda K, Kumada H, Saitoh S, Arase Y, Chayama K. Effect of repeated transcatheter arterial embolization on the survival time in patients with hepatocellular carcinoma. An analysis by the Cox proportional hazard model. Cancer 1991; 68 (10) 2150-2154
  • 37 Herber SC, Otto G, Schneider J , et al. Transarterial chemoembolization in patients not eligible for liver transplantation: single-center results. AJR Am J Roentgenol 2008; 190 (4) 1035-1042
  • 38 Ernst O, Sergent G, Mizrahi D, Delemazure O, Paris JC, L'Herminé C. Treatment of hepatocellular carcinoma by transcatheter arterial chemoembolization: comparison of planned periodic chemoembolization and chemoembolization based on tumor response. AJR Am J Roentgenol 1999; 172 (1) 59-64
  • 39 Forner A, Ayuso C, Varela M , et al. Evaluation of tumor response after locoregional therapies in hepatocellular carcinoma: are response evaluation criteria in solid tumors reliable?. Cancer 2009; 115 (3) 616-623
  • 40 Llovet JM, Ricci S, Mazzaferro V , et al; SHARP Investigators Study Group. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 2008; 359 (4) 378-390
  • 41 Kulik LM, Carr BI, Mulcahy MF , et al. Safety and efficacy of 90Y radiotherapy for hepatocellular carcinoma with and without portal vein thrombosis. Hepatology 2008; 47 (1) 71-81
  • 42 Hsu CY, Hsia CY, Huang YH , et al. Comparison of surgical resection and transarterial chemoembolization for hepatocellular carcinoma beyond the Milan criteria: a propensity score analysis. Ann Surg Oncol 2012; 19 (3) 842-849
  • 43 Zhang ZM, Guo JX, Zhang ZC, Jiang N, Zhang ZY, Pan LJ. Therapeutic options for intermediate-advanced hepatocellular carcinoma. World J Gastroenterol 2011; 17 (13) 1685-1689
  • 44 Silva MF, Sherman M. Criteria for liver transplantation for HCC: what should the limits be?. J Hepatol 2011; 55 (5) 1137-1147
  • 45 Mazzaferro V, Llovet JM, Miceli R , et al; Metroticket Investigator Study Group. Predicting survival after liver transplantation in patients with hepatocellular carcinoma beyond the Milan criteria: a retrospective, exploratory analysis. Lancet Oncol 2009; 10 (1) 35-43
  • 46 Clavien PA, Lesurtel M, Bossuyt PM, Gores GJ, Langer B, Perrier A. OLT for HCC Consensus Group. Recommendations for liver transplantation for hepatocellular carcinoma: an international consensus conference report. Lancet Oncol 2012; 13 (1) e11-e22
  • 47 Jelic S, Sotiropoulos GC. ESMO Guidelines Working Group. Hepatocellular carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2010; 21 (Suppl. 05) v59-v64
  • 48 Ravaioli M, Grazi GL, Piscaglia F , et al. Liver transplantation for hepatocellular carcinoma: results of down-staging in patients initially outside the Milan selection criteria. Am J Transplant 2008; 8 (12) 2547-2557
  • 49 Vibert E, Azoulay D, Hoti E , et al. Progression of alphafetoprotein before liver transplantation for hepatocellular carcinoma in cirrhotic patients: a critical factor. Am J Transplant 2010; 10 (1) 129-137
  • 50 Yao FY, Kerlan Jr RK, Hirose R , et al. Excellent outcome following down-staging of hepatocellular carcinoma prior to liver transplantation: an intention-to-treat analysis. Hepatology 2008; 48 (3) 819-827
  • 51 Llovet JM, Ricci S, Mazzaferro V , et al. Sorafenib improves survival in advanced hepatocellular carcinoma (HCC): results of a Phase III randomized placebo-controlled trial (SHARP trial). Paper presented at: American Society of Clinical Oncology Annual Meeting; June 1–5, 2007; Chicago, IL
  • 52 Cheng AL, Kang YK, Chen Z , et al. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol 2009; 10 (1) 25-34
  • 53 Bruix J, Raoul JL, Sherman M , et al. Efficacy and safety of sorafenib in patients with hepatocellular carcinoma (HCC): Subanalysis of SHARP trial based on Barcelona Clinic Liver Cancer (BCLC) stage. J Hepatol 2009; 50 (Suppl. 01) S28-S29
  • 54 Lencioni R, Venook AP, Marrero JA , et al. Second Interim Results of the GIDEON (Global Investigation of Therapeutic DEcisions in HCC and of Its Treatment With SorafeNib) Study - Barcelona-Clinic Liver Cancer (BCLC) Stage Subgroup Analysis. Abs 6500. Abstract presented at: The European Multidisciplinary Cancer Congress; September 23–27, 2011; Stockholm, Sweden
  • 55 Marrero JA, Lencioni R, Kudo M , et al. Global Investigation of Therapeutic Decisions in Hepatocellular Carcinoma and of its Treatment with Sorafenib (GIDEON) second interim analysis in more than 1,500 patients: Clinical findings in patients with liver dysfunction. J Clin Oncol 2011; 29: 4001
  • 56 Iavarone M, Cabibbo G, Piscaglia F , et al; SOFIA (SOraFenib Italian Assessment) study group. Field-practice study of sorafenib therapy for hepatocellular carcinoma: a prospective multicenter study in Italy. Hepatology 2011; 54 (6) 2055-2063
  • 57 Piscaglia F, Trimarchi C, Terzi E , et al. The rate of HCC patients in Child-Pugh B untreatable with effective strategies according to AASLD guidelines increases with the progression of specific Child-Pugh score. Hepatology 2010; 52: 1168A
  • 58 Burrel M, Reig M, Forner A , et al. Survival of patients with hepatocellular carcinoma treated by transarterial chemoembolisation (TACE) using drug eluting beads. Implications for clinical practice and trial design. J Hepatol 2012; 56 (6) 1330-1335
  • 59 Salem R, Lewandowski RJ, Mulcahy MF , et al. Radioembolization for hepatocellular carcinoma using Yttrium-90 microspheres: a comprehensive report of long-term outcomes. Gastroenterology 2010; 138 (1) 52-64
  • 60 Hilgard P, Hamami M, Fouly AE , et al. Radioembolization with yttrium-90 glass microspheres in hepatocellular carcinoma: European experience on safety and long-term survival. Hepatology 2010; 52 (5) 1741-1749
  • 61 Sangro B, Carpanese L, Cianni R , et al; European Network on Radioembolization with Yttrium-90 Resin Microspheres (ENRY). Survival after yttrium-90 resin microsphere radioembolization of hepatocellular carcinoma across Barcelona clinic liver cancer stages: a European evaluation. Hepatology 2011; 54 (3) 868-878
  • 62 Sangro B, Iñarrairaegui M, Bilbao JI. Radioembolization for hepatocellular carcinoma. J Hepatol 2012; 56 (2) 464-473
  • 63 Andreana L, Isgrò G, Marelli L , et al. Treatment of hepatocellular carcinoma (HCC) by intra-arterial infusion of radio-emitter compounds: trans-arterial radio-embolisation of HCC. Cancer Treat Rev 2012; 38 (6) 641-649
  • 64 Iñarrairaegui M, Pardo F, Bilbao JI , et al. Response to radioembolization with yttrium-90 resin microspheres may allow surgical treatment with curative intent and prolonged survival in previously unresectable hepatocellular carcinoma. Eur J Surg Oncol 2012; 38 (7) 594-601
  • 65 Lewandowski RJ, Kulik LM, Riaz A , et al. A comparative analysis of transarterial downstaging for hepatocellular carcinoma: chemoembolization versus radioembolization. Am J Transplant 2009; 9 (8) 1920-1928
  • 66 Lencioni R. Management of hepatocellular carcinoma with transarterial chemoembolization in the era of systemic targeted therapy. Crit Rev Oncol Hematol 2012; 83 (2) 216-224
  • 67 Li X, Feng GS, Zheng CS, Zhuo CK, Liu X. Expression of plasma vascular endothelial growth factor in patients with hepatocellular carcinoma and effect of transcatheter arterial chemoembolization therapy on plasma vascular endothelial growth factor level. World J Gastroenterol 2004; 10 (19) 2878-2882
  • 68 Carmeliet P, Jain RK. Angiogenesis in cancer and other diseases. Nature 2000; 407 (6801) 249-257
  • 69 Dufour JF, Hoppe H, Heim MH , et al. Continuous administration of sorafenib in combination with transarterial chemoembolization in patients with hepatocellular carcinoma: results of a phase I study. Oncologist 2010; 15 (11) 1198-1204
  • 70 Chung Y, Kim B, Chen C , et al. Study in Asia of the combination of transcatheter arterial chemoembolization (TACE) with sorafenib in patients with hepatocellular carcinoma (HCC) trial (START): Second interim safety and efficacy analysis. J Clin Oncol 2010; 28: 4026
  • 71 Lencioni R, Llovet JM, Han G , et al. Sorafenib or placebo in combination with transarterial chemoembolization (TACE) with doxorubicin-eluting beads (DEBDOX) for intermediate-stage hepatocellular carcinoma (HCC): Phase II, randomized, double-blind SPACE trial. . [Abstract LBA154] J Clin Oncol 2012; 30 (suppl)
  • 72 Akamatsu M, Yoshida H, Obi S , et al. Evaluation of transcatheter arterial embolization prior to percutaneous tumor ablation in patients with hepatocellular carcinoma: a randomized controlled trial. Liver Int 2004; 24 (6) 625-629
  • 73 Bartolozzi C, Lencioni R, Caramella D , et al. Treatment of large HCC: transcatheter arterial chemoembolization combined with percutaneous ethanol injection versus repeated transcatheter arterial chemoembolization. Radiology 1995; 197 (3) 812-818
  • 74 Becker G, Soezgen T, Olschewski M, Laubenberger J, Blum HE, Allgaier HP. Combined TACE and PEI for palliative treatment of unresectable hepatocellular carcinoma. World J Gastroenterol 2005; 11 (39) 6104-6109
  • 75 Marelli L, Stigliano R, Triantos C , et al. Treatment outcomes for hepatocellular carcinoma using chemoembolization in combination with other therapies. Cancer Treat Rev 2006; 32 (8) 594-606
  • 76 Cheung TT, Ng KK, Chok KS , et al. Combined resection and radiofrequency ablation for multifocal hepatocellular carcinoma: prognosis and outcomes. World J Gastroenterol 2010; 16 (24) 3056-3062
  • 77 NCCN. NCCN Clinical Practice Guidelines in Oncology. Hepatobiliary Cancer. V2.2012. Available at: www.nccn.org . Accessed August 24, 2012
  • 78 Kudo M, Izumi N, Kokudo N , et al; HCC Expert Panel of Japan Society of Hepatology. Management of hepatocellular carcinoma in Japan: consensus-based clinical practice guidelines proposed by the Japan Society of Hepatology (JSH) 2010 updated version. Dig Dis 2011; 29 (3) 339-364
  • 79 Omata M, Lesmana LA, Tateishi R , et al. Asian Pacific Association for the Study of the Liver consensus recommendations on hepatocellular carcinoma. Hepatol Int 2010; 4 (2) 439-474
  • 80 Tournoux-Facon C, Paoletti X, Barbare JC , et al. Development and validation of a new prognostic score of death for patients with hepatocellular carcinoma in palliative setting. J Hepatol 2011; 54 (1) 108-114
  • 81 Llovet JM, Bustamante J, Castells A , et al. Natural history of untreated nonsurgical hepatocellular carcinoma: rationale for the design and evaluation of therapeutic trials. Hepatology 1999; 29 (1) 62-67
  • 82 Bruix J, Sala M, Llovet JM. Chemoembolization for hepatocellular carcinoma. Gastroenterology 2004; 127 (5) (Suppl. 01) S179-S188